SCHEMBL6096595

SCHEMBL6096595

O=c1cc(C(F)(F)F)c2cc(Cc3ccc(NC(=S)NCc4ccccc4)cc3)ccc2[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 7/20 0.53
MAPT P10636 5/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
GAA P10253 2/20 0.52
ALDH1A1 P00352 1/20 0.52
LSS P48449 1/20 0.50
MYC P01106 1/20 0.48
MAX P61244 1/20 0.48
LMNA P02545 2/20 0.48
ALOX12 P18054 1/20 0.48
HTT P42858 1/20 0.48
HPGD P15428 2/20 0.47
CYP2C9 P11712 1/20 0.47
ATM Q13315 1/20 0.47
PLA2G1B P04054 1/20 0.47
ATG4B Q9Y4P1 1/20 0.47
POLB P06746 1/20 0.46
RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6095163 0.91 MEN1 (0.52) ARMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL6097934 0.91 KDM4E (0.54) ARMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL6096236 0.89 ALDH1A1 (0.54) ARMAPTMEN1KMT2AGAA
SCHEMBL6098243 0.86 LMNA (0.56) ARGAALMNAHPGDCYP2C9
SCHEMBL6095168 0.85 LMNA (0.48) ARLMNAHPGDCYP2C9
SCHEMBL6096023 0.85 SMN1; SMN2 (0.56) MAPTMEN1KMT2ASMN1; SMN2GAA
SCHEMBL6078127 0.83 AR (0.55) ARMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL5761325 0.83 AR (0.61) AR
SCHEMBL6112427 0.83 LMNA (0.54) ARLMNAHPGDCYP2C9
SCHEMBL6097519 0.82 LMNA (0.50) ARMAPTMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115745-B2 Benzyl urea and thiourea derivatives WARNER LAMBERT COMPANY LLC (US) 2006-10-03 US claimed
EP-1597233-A1 BENZYL UREA AND THIOUREA DERIVATIVES USEFUL AS ANDROGEN ANTAGONISTS Warner-Lambert Company LLC (US) 2005-11-23 EP claimed
WO-2004072043-A1 BENZYL UREA AND THIOUREA DERIVATIVES USEFUL AS ANDROGEN ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2004-08-26 WO claimed
US-7115745-B2 Benzyl urea and thiourea derivatives WARNER LAMBERT COMPANY LLC (US) 2006-10-03 US disclosed
EP-1597233-A1 BENZYL UREA AND THIOUREA DERIVATIVES USEFUL AS ANDROGEN ANTAGONISTS Warner-Lambert Company LLC (US) 2005-11-23 EP disclosed
US-20050107427-A1 Benzyl urea and thiourea derivatives DU DANIEL Y (US) 2005-05-19 US disclosed
WO-2004072043-A1 BENZYL UREA AND THIOUREA DERIVATIVES USEFUL AS ANDROGEN ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107427-A1 Benzyl urea and thiourea derivatives BRDT, TAS2R8, FSHR AR 9/4885MAPT 4365/4885MEN1 4659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.